Skip to main content
PMC home page
PLOS ONE logoLink to PLOS ONE
. 2012 May 11;7(5):e36813. doi: 10.1371/journal.pone.0036813

Cyclin D1 G870A Polymorphism Contributes to Colorectal Cancer Susceptibility: Evidence from a Systematic Review of 22 Case-Control Studies

Yongzhi Yang 1,2, Feng Wang 1, Chenzhang Shi 2, Yang Zou 2, Huanlong Qin 1,*, Yanlei Ma 1,*
Editor: Amanda Ewart Toland3
PMCID: PMC3350479  PMID: 22606291

Abstract

Background

Cyclin D1 (CCND1) plays a vital role in cancer cell cycle progression. Numerous epidemiological studies have evaluated the association between the CCND1 G870A polymorphism and the risk of colorectal cancer. However, these studies have yielded conflicting results. To derive a more precise estimation of this association, we conducted a meta-analysis and systematic review.

Methodology/Principal Findings

A comprehensive search was conducted to identify eligible studies of the CCND1 G870A polymorphism and colorectal cancer risk. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were derived from a fixed effect or random effect model. We applied a grading system (Venice criteria) that assessed the epidemiological strength of the association. A total of 22 publications that included 6157 cases and 8198 controls were identified. We found that the CCND1 G870A polymorphism was significantly associated with overall colorectal cancer risk (homozygote genetic model: OR = 1.130, 95% CI = 1.023–1.248, P = 0.016; heterozygote genetic model: OR = 1.124, 95% CI = 1.030–1.226, P = 0.009; dominant genetic model: OR = 1.127, 95% CI = 1.037–1.224, P = 0.005). After further stratified analyses, the increased risk was observed only in the subgroups of hospital-based studies, PCR-RFLP genotyping methods, sporadic colorectal cancer, and Caucasian ethnicity.

Conclusions

The available evidence demonstrates that the CCND1 870A allele might be a low-penetrant risk factor for colorectal cancer.

Introduction

Colorectal cancer (CRC) is the second most common type of cancer in women and the third most common type in men in the United States and Europe [1], [2]. The multistep carcinogenesis of the adenoma-carcinoma sequence is determined by caretaker molecular pathways, and this conventional theory is also thought to describe colorectal oncogenesis [3], [4]. However, it is now commonly accepted that the pathogenesis of CRC involves the multi-factorial interactions of environmental triggers and genetic susceptibility [5]. A recent study have revealed that approximately 35% of CRC cases can be attributed to inherited genetic susceptibility [5].

The adenine-to-guanine (A/G) substitution at nucleotide 870 (CCND1 G870A polymorphism, rs603965) and excessive cyclin D1 activity are common in numerous human tumors, including breast cancer, lung cancer, head and neck cancers, gastric cancer, gynecological cancers, blood-related cancers, and CRC [6], [7]. Although various studies have linked the CCND1 G870A polymorphism to increased CRC risk, the results remain controversial. To further investigate the combined effect of the CCND1 G870A polymorphism on CRC susceptibility, we performed a meta-analysis and systematic review.

Methods

Identification and Eligibility of Relevant Studies

All published literature investigating an association between the CCND1 G870A polymorphism and colorectal cancer risk were eligible. We searched for studies using the PubMed database up to October 2011. The relevant search terms “G870A”, “A870G”, “CCND1”, “cyclin D1”, “polymorphism”, ”cancer”, “colorectal”, “colonic”, “colon”, “rectal”, “rectum”, and “humans” were used. Both free text and a MeSH search for keywords were employed. We also manually searched the reference lists in selected articles and the abstracts published at major international conferences. Abstracts that were not written in English were excluded. All the studies met the following criteria: (1) the CCND1 G870A polymorphism was determined; (2) the outcome had to be colorectal cancer in humans. The major exclusion criteria were (1) reviews, tutorials, letters, and editorials; (2) duplicate data; (3) not a case-control design; (4) insufficient data were reported as cyclin D1 expression levels were provided without genotype data; (5) overlapping data and data superseded by the latest reports.

Data Extraction

Data were extracted independently and crosschecked against the research consensus. The following variables were recorded: the first author’s last name; publication year; region/country where the study was performed; participant gender; ethnicity (included Caucasian, Asian and Mixed) of the study population; epidemiological type of colorectal cancer (included hereditary nonpolyposis colorectal cancer (HNPCC), sporadic colorectal cancer (sCRC), and sporadic colonic cancer (sCC)); histopathological subgroup information if known (included Dukes’ stage (A/B and C/D) and degree of differentiation (well/moderate, moderate and poor)); control source (family-based study (FB), population-based study (PB), and hospital-based study (HB)); genotyping method (polymerase chain reaction (PCR) single-stranded conformation polymorphism (PCR-SSCP), PCR restriction fragment length polymorphism (PCR-RFLP), high-performance liquid chromatography (HPLC), TaqMan PCR, and DNA sequencing); sample size (total cases and controls as well as the numbers of cases and controls with G/G, G/A, and A/A genotypes); and the P value of the Hardy-Weinberg equilibrium in the control group. Only the latest studies were included when the data sets overlapped or were duplicated. The primary authors were contacted to provide additional information when necessary. Study identification and data extraction were conducted independently by three investigators and checked for accuracy by one author.

Statistical Analysis

Dichotomous variables were pooled using an odds ratio (OR). The summary OR was replaced by the risk difference (RD) if one of the studies reported no events in either the case group or the control group.

The wild type G/G genotype was considered as a reference. Pooled effects were calculated for a homozygote comparison model (A/A vs. G/G), a heterozygote comparison model (G/A vs. G/G), a dominant model (G/A+A/A vs. G/G), and a recessive model (A/A vs. G/G+G/A).

The statistical heterogeneity between included studies was determined using the chi-square-based Q-test [8], [9]. According to the Higgins’ I2 statistic, heterogeneity was defined as low or moderate if less than 50% and high if greater than 50% [8]. A fixed effect model was applied using the Mantel-Haenszel method for low or moderate statistical heterogeneous studies [10]. A random effect model, which assumed that the studies involved came from a random sample of a hypothetical population of studies that took into account heterogeneity, was used when heterogeneity was high [11]. A Galbraith plot was created to graphically assess the extent of heterogeneity between studies from the current meta-analysis [12], [13]. A L’Abbé plot was used for the additionally assessment of colorectal cancer risk [14], [15]. The Hardy-Weinberg equilibrium (HWE) was determined using the chi-square test in the control groups [16].

Sensitivity analyses were conducted either by replacing a value of effect with another or removing individual studies from the data set. Sensitivity analyses were also performed by excluding studies in which the genotype frequencies in the controls significantly deviated from the HWE. We conducted subgroup analyses of the study design, cancer type, cancer location, ethnicity, Dukes’ stage, degree of differentiation, gender and genotyping method to investigate potential sources of heterogeneity.

Publication bias among the included studies was assessed graphically using a Begg’s funnel plot [17]. Additionally, publication bias was also evaluated statistically with an Egger’s test [18].

The study confidence interval (CI) was established at 95%. Two-tailed P values of less than 0.05 were considered statistically significant. All statistical analyses were performed using the STATA version 11.0 software (Stata Corporation, College Station, TX).

Assessment of Cumulative Evidence

The Venice criteria [19] were developed by the Human Genome Epidemiology Network (HuGENet) Working Group to assess the cumulative epidemiological strength of genetic association studies; these same criteria were applied in this study. Following the Venice criteria, our meta-analysis was graded based on three categories: (1) the amount of evidence (sample sizes of cases and controls that were greater than 1000, 100–1000, or less than 100 were assigned a grade of A, B, or C, respectively); (2) the extent of replication (a Higgins’ I2 statistic [8] that was less than 25%, 25% – 50% or greater than 50% was assigned a grade of A, B, or C, respectively); (3) protection from bias (a grade of A was assigned if there was no observable bias, a grade of B was assigned if bias could be present or could explain the presence of the association; a grade of C was assigned if bias was considerable and had an effect even the presence or absence of the association).

Results

Characteristics of the Studies

Through literature search and selection, a total of 22 publications [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41] including 6157 cases and 8198 controls comparing the CCND1 G870A polymorphism and colorectal cancer susceptibility were identified based on MOOSE (Meta-analysis Of Observational Studies in Epidemiology) guidelines [42]. Two studies [24], [35] investigated both HNPCC and sCRC, and the genotype frequencies were therefore separated into three types: Mixed, HNPCC, and sCRC. One article [26] mentioned two independent populations (Asians and Caucasians), and the study was thus treated as three separate estimates: Mixed, Asians, and Caucasians. A flow chart of the inclusion and exclusion criteria is presented in Figure 1 .

Figure 1. Flow chart of study selection according to MOOSE guidelines [42].

Figure 1

Open in a new tab

Five articles [20], [26], [34], [37], [39] showed mixed or missing ethnicity data. Nine studies [24], [30], [32], [33], [34], [35], [37], [40], [41] showed mixed types of cancer data. Of the 22 included studies, 2 were family-based [20], [22], 11 were population-based [21], [23], [24], [26], [28], [31], [32], [33], [37], [38], [40], and 9 were hospital-based [25], [27], [29], [30], [34], [35], [36], [39], [41]. Multiple genotyping methods were employed in the studies and included PCR-RFLP, PCR-SSCP, HLC, TaqMan PCR, and DNA sequencing. The distribution of genotypes in the controls of all studies was consistent with Hardy-Weinberg equilibrium except in one study [29]. Characteristics of the studies included are summarized in Table 1 .

Table 1. Characteristics of the studies included in the meta-analysis.

First author (Year) Country Ethnicity Type of cancer Source of controls Genotyping method Total, N GG genotype, N GA genotype, N AA genotype, N HWE Reference
Cases Controls Cases Controls Cases Controls Cases Controls
Kong (2000) US Mixed HNPCC FB PCR-SSCP 49 37 9 10 36 21 4 6 0.51 [20]
McKay (2000) UK Caucasian sCRC PB PCR-RFLP 100 101 25 34 58 50 17 17 0.849 [21]
Bala (2001) Finland Caucasian HNPCC FB PCR-SSCP 146 186 50 47 70 97 26 42 0.551 [22]
Kong (2001) US Caucasian sCRC PB PCR-SSCP 156 152 36 45 71 84 49 23 0.112 [20]
Porter (2002) UK Caucasian Mixed PB PCR-RFLP 334 171 85 60 175 81 74 30 0.768 [24]
Porter (2002) UK Caucasian HNPCC PB PCR-RFLP 99 171 30 60 47 81 22 30 0.768 [24]
Porter (2002) UK Caucasian sCRC PB PCR-RFLP 128 171 34 60 65 81 29 30 0.768 [24]
Grieu (2003) Australia Caucasian sCRC HB PCR-SSCP 569 327 142 90 313 158 114 79 0.556 [25]
Le Marchand (2003) US Mixed Mixed PB PCR-RFLP 504 624 109 164 253 315 142 145 0.792 [26]
Le Marchand (2003) US Caucasian sCRC PB PCR-RFLP 138 161 29 50 75 85 34 26 0.311 [26]
Le Marchand (2003) US Asian sCRC PB PCR-RFLP 296 380 75 96 143 195 78 89 0.603 [26]
Lewis (2003) US Caucasian sCRC HB PCR-RFLP 161 213 51 84 84 98 26 31 0.781 [27]
Hong (2005) Singapore Asian sCRC PB PCR-RFLP 254 101 55 12 128 50 71 39 0.505 [28]
Huang (2006) Taiwan Asian sCRC HB PCR-RFLP 831 1052 126 199 411 464 294 389 0.004 [29]
Jiang (2006) India Asian Mixed HB PCR-RFLP 301 291 46 56 130 145 125 90 0.86 [30]
Kruger (2006) Germany Caucasian HNPCC PB Multiplex PCR 315 245 110 73 144 121 61 51 0.947 [31]
Probst-Hensch (2006) Singapore Asian Mixed PB TaqMan PCR 300 1169 56 207 132 548 112 414 0.272 [32]
Schernhammer (2006) US Caucasian Mixed PB TaqMan PCR 610 1237 125 264 311 593 174 380 0.25 [33]
Forones (2008) Brazil Mixed Mixed HB PCR-RFLP 123 120 36 34 66 67 21 19 0.141 [34]
Grunhage (2008) Germany Caucasian Mixed HB PCR-RFLP 194 218 37 48 93 109 64 61 0.958 [35]
Grunhage (2008) Germany Caucasian HNPCC HB PCR-RFLP 98 218 13 48 50 109 35 61 0.958 [35]
Grunhage (2008) Germany Caucasian sCRC HB PCR-RFLP 96 218 24 48 43 109 29 61 0.958 [35]
Talseth (2008) Australia/Poland Caucasian HNPCC HB TaqMan PCR 157 153 34 42 78 80 45 31 0.527 [36]
Tan (2008) Germany Mixed Mixed PB PCR-RFLP 498 600 120 147 263 310 115 143 0.414 [37]
Jelonek (2010) Poland Caucasian sCC PB PCR-RFLP 50 153 12 44 33 71 5 38 0.383 [38]
Kanaan (2010) US NS sCRC HB PCR-HLC 75 93 19 24 39 48 17 21 0.748 [39]
Liu (2010) China Asian Mixed PB PCR-RFLP 373 838 66 160 187 429 120 249 0.303 [40]
Yaylim-Eraltan (2010) Turkey Caucasian Mixed HB PCR-RFLP 57 117 9 29 28 60 20 28 0.781 [41]
Open in a new tab

HWE: Hardy–Weinberg equilibrium; US: United States; UK: United Kingdom; HNPCC: hereditary nonpolyposis colorectal cancer; sCRC: sporadic colorectal cancer; sCC: sporadic colonic cancer; FB: family-based study; PB: population-based study; HB: hospital-based study; PCR: polymerase chain reaction; SSCP: single-stranded conformation polymorphism; RFLP: restriction fragment length polymorphism; HPLC: high-performance liquid chromatography.

Heterogeneity Analysis

The genotype data in the 22 studies were homogenous for the heterozygote genetic model (G/A vs. G/G: Q-test = 23.65, P = 0.310, I2 = 11.20) and the dominant genetic model (G/A+A/A vs. G/G: Q-test = 27.93, P = 0.142, I2 = 24.80), but heterogeneity was significant for the homozygote genetic model (A/A vs. G/G: Q-test = 39.53, P = 0.008, I2 = 46.90) and the recessive genetic model (A/A vs. G/G+G/A: Q-test = 27.93, P = 0.142, I2 = 52.70).

Galbraith plot analyses of all included studies were used to assess the potential sources of heterogeneity. Two studies [20], [41] were found to be contributors of heterogeneity in the homozygote comparison model ( Figure 2 ).

Figure 2. Galbraith plot [12] analysis of the amount of heterogeneity from all the included studies (AA vs. GG).

Figure 2

Open in a new tab

The y-axis shows the ratio of the log OR to its standard error (SE), and the x-axis shows the reciprocal of the SE. Each study is represented by the name of the first author. A regression line runs centrally through the name. At a 2 standard deviation distance parallel to the regression line, the 2 lines create an interval. Studies lacking in heterogeneity would lie within the 95% confidence interval (positioned 2 units above and below the central regression line).

Association of the CCND1 G870A Polymorphism with CRC Susceptibility

The multivariable-adjusted ORs for each study and the OR for the combination of all the studies are shown in Table 2 ; these ORs were used to determine the association of the G870A polymorphism with CRC susceptibility. A significant association of the G870A polymorphism with CRC susceptibility was observed in the homozygote comparison model, the heterozygote comparison model, and the dominant model when all the studies were considered (A/A vs. G/G: OR = 1.130, 95% CI = 1.023–1.248, P = 0.016; G/A vs. G/G: OR = 1.124, 95% CI = 1.030–1.226, P = 0.009; G/A+A/A vs. G/G: OR = 1.127, 95% CI = 1.037–1.224, P = 0.005), However, the association was not observed in the recessive genetic model (A/A vs. G/G+G/A: OR = 1.067, 95% CI = 0.941–1.210, P = 0.311).

Table 2. Meta-analysis of the association between the CCND1 G870A polymorphism and colorectal cancer risk.

Study group Homozygote comparison: A/A vs. G/G Heterozygote comparison: G/A vs. G/G Dominant model: G/A+A/A vs. G/G Recessive model: A/A vs. G/A+G/G PE >0.05
OR (95% CI) P ChiH 2 (PH) I2, % OR (95% CI) P ChiH 2 (PH) I2, % OR (95% CI) P ChiH 2 (PH) I2, % OR (95% CI) P ChiH 2 (PH) I2, %
Total 1.130(1.023 – 1.248) 0.016 39.53(0.008) 46.90 1.124 (1.030 – 1.226) 0.009 23.65 (0.310) 11.20 1.127(1.037 – 1.224) 0.005 27.93 (0.142) 24.80 1.067(0.941 – 1.210) 0.311 44.42 (0.002) 52.70 Y
Study design: PB 1.092(0.872 – 1.367) 0.442 25.62(0.004) 61.00 1.073 (0.959 – 1.201) 0.22 13.08 (0.220) 23.50 1.082(0.973 – 1.204) 0.147 16.73 (0.081) 40.20 1.044(0.944 – 1.154) 0.405 26.05 (0.004) 61.60 Y
Study design: HB 1.260(1.072 – 1.482) 0.005 10.06(0.345) 10.60 1.249 (1.082 – 1.442) 0.002 5.76 (0.764) 0.00 1.252(1.093 – 1.433) 0.001 5.94 (0.746) 0.00 1.079(0.955 – 1.219) 0.224 15.90 (0.069) 43.40 Y
Type of cancer: HNPCC 1.132(0.728 – 1.761) 0.581 11.83(0.037) 57.70 0.984 (0.790 – 1.227) 0.886 8.06 (0.153) 38.00 1.085(0.779 – 1.510) 0.63 11.03 (0.051) 54.70 1.096(0.877 – 1.371) 0.42 7.64 (0.177) 34.50 Y
Type of cancer: sCRC 1.160(0.889 – 1.514) 0.273 23.65(0.009) 57.70 1.204 (1.053 – 1.376) 0.007 12.24 (0.269) 18.30 1.188(1.046 – 1.348) 0.008 13.45 (0.200) 25.60 1.058(0.841 – 1.333) 0.629 27.61 (0.002) 63.80 Y
Location: Colon 1.228(0.963 – 1.567) 0.098 4.88(0.430) 0.00 0.984 (0.661 – 1.465) 0.938 13.69 (0.018) 63.50 1.112(0.947 – 1.304) 0.194 10.81 (0.147) 35.20 1.219(0.880 – 1.689) 0.234 10.74 (0.057) 53.50 Y
Location: Rectum 1.177(0.645 – 2.149) 0.595 15.07(0.005) 73.50 0.836 (0.385 – 1.814) 0.65 32.81 (<0.001) 87.80 0.913(0.500 – 1.664) 0.766 39.89 (<0.001) 87.50 1.224(1.001 – 1.497) 0.048 6.37 (0.173) 37.20 Y
Ethnicity: Asian 1.093(0.854 – 1.399) 0.48 11.14(0.049) 55.10 1.073 (0.927 – 1.243) 0.344 8.90 (0.113) 43.80 1.09(0.949 – 1.251) 0.223 9.42 (0.093) 46.90 1.068(0.883 – 1.292) 0.498 12.49 (0.029) 60.00 Y
Ethnicity: Caucasian (all) 1.306(0.996 – 1.713) 0.053 29.79(0.003) 59.70 1.145 (1.004 – 1.306) 0.043 16.63 (0.164) 27.90 1.162(1.026 – 1.316) 0.018 21.58 (0.043) 44.40 1.181(0.951 – 1.465) 0.132 27.9 (0.006) 57.00 Y
Ethnicity: Caucasian (HNPCC) 1.170(0.725 – 1.888) 0.521 11.59(0.021) 65.50 0.954 (0.762 – 1.196) 0.685 6.45 (0.168) 38.00 1.049(0.737 – 1.492) 0.791 10.09 (0.039) 60.40 1.125(0.897 – 1.411) 0.31 5.97 (0.201) 33.00 Y
Ethnicity: Caucasian (sCRC) 1.511(1.158 – 1.972) 0.002 10.21(0.116) 41.20 1.307 (1.057 – 1.617) 0.014 4.57 (0.600) 0.00 1.369(1.118 – 1.676) 0.002 3.71 (0.716) 0.00 1.249(0.865 – 1.805) 0.236 14.72 (0.023) 59.20 Y
Dukes’ stage: A/B 1.114(0.895 – 1.385) 0.334 1.76(0.623) 0.00 1.072 (0.876 – 1.312) 0.498 5.04 (0.169) 40.50 1.061(0.883 – 1.275) 0.529 4.41 (0.353) 9.30 1.052(0.893 – 1.241) 0.544 4.02 (0.259) 25.40 Y
Dukes’ stage: C/D 1.275(1.007 – 1.613) 0.043 5.23(0.156) 42.60 1.365 (1.097 – 1.698) 0.005 1.07 (0.785) 0.00% 1.105(0.754 – 1.618) 0.609 12.17 (0.016) 67.10 1.020(0.861 – 1.209) 0.816 5.60 (0.133) 46.40 Y
Degree of differentiation:Well/Moderate 1.199(0.932 – 1.541) 0.157 0.01(0.996) 0.00 1.337 (1.063 – 1.682) 0.013 1.38 (0.501) 0.00 1.022(0.679 – 1.538) 0.916 7.44 (0.059) 59.70 0.948(0.791 – 1.137) 0.556 0.81 (0.666) 0.00 Y
Degree of differentiation:Poor *0.079(−0.369 – 0.527) 0.73 16.75(<0.001) 88.10 *0.072 (−0.298 – 0.443) 0.702 18.67 (<0.001) 89.30 *0.004(−0.228 – 0.236) 0.972 26.19 (<0.001) 88.50 *−0.004(−0.111 – 0.104) 0.943 3.56 (0.168) 43.80 Y
Gender: Female 1.141(0.835 – 1.559) 0.408 2.10(0.552) 0.00 1.290 (0.975 – 1.708) 0.074 2.84 (0.417) 0.00 1.282(1.003 – 1.639) 0.047 3.99 (0.407) 0.00 0.932(0.743 – 1.170) 0.545 0.48 (0.924) 0.00 Y
Gender: Male 1.318(0.991 – 1.752) 0.058 5.85(0.119) 48.70 1.393 (1.073 – 1.809) 0.013 2.90 (0.407) 0.00 1.359(1.080 – 1.710) 0.009 4.02 (0.403) 0.50 1.237(0.770 – 1.986) 0.379 6.94 (0.074) 56.80 Y
Genotyping method: PCR-RFLP 1.262 (1.126 – 1.415) <0.001 26.80(0.083) 32.8 1.190 (1.076 – 1.315) 0.001 17.40 (0.496) 0.00 1.216(1.106 – 1.337) <0.001 20.29 (0.317) 11.3 1.118(1.023 – 1.221) 0.014 27.62 (0.068) 34.8 Y
Genotyping method: PCR-SSCP 1.050 (0.539 – 2.047) 0.886 11.59(0.009) 74.1 1.080 (0.852 – 1.369) 0.527 5.23 (0.156) 42.7 1.070(0.745 – 1.538) 0.713 6.17 (0.104) 51.4 0.992(0.516 – 1.907) 0.980 15.41 (0.001) 80.5 Y
Genotyping method: TaqMan PCR 1.044 (0.848 – 1.286) 0.684 3.06(0.216) 34.7 1.049 (0.865 – 1.272) 0.626 1.26 (0.533) 0.00 1.049(0.875 – 1.258) 0.602 1.46 (0.482) 0.00 1.066(0.827 – 1.373) 0.623 4.22 (0.121) 52.6 Y
Open in a new tab

ChiH 2 and PH: chi-squared and P values of the Q-test of heterogeneity; HNPCC: hereditary nonpolyposis colorectal cancer; sCRC: sporadic colorectal cancer; sCC: sporadic colonic cancer; PB: population-based study; HB: hospital-based study; PCR: polymerase chain reaction; RFLP: restriction fragment length polymorphism; SSCP: single-stranded conformation polymorphism; HPLC: high-performance liquid chromatography; PE: Egger’s test in each model; Y: yes; *: pooled OR was replaced with RD.

Stratifying Analyses

We conducted subgroup analyses, and the results are listed in Table 2 . Additionally, the L’Abbé plot was also used to assess the CRC risk in each group in all included studies ( Figure 3 ).

Figure 3. The L’Abbé plot [14] for the assessment of CRC risk in each group (G/A+A/A vs. G/G).

Figure 3

Open in a new tab

Each circle represents individual trial sizes, and the circles are proportional to the study weights (participant number). The diagonal dotted line indicates that the CRC risk was equal in the two arms within the trials. The solid regression line represented a summary OR of 1.127 (G/A+A/A vs. G/G), which was estimated from the pooled results of all 22 studies.

Significant association of the CCND1 G870A polymorphism with CRC risk was observed in many subgroup categories, including subsets of hospital-based studies (A/A vs. G/G: OR = 1.260, 95% CI = 1.072–1.482, P = 0.005; G/A vs. G/G: OR = 1.249, 95% CI = 1.082–1.442, P = 0.002; G/A+A/A vs. G/G: OR = 1.252, 95% CI = 1.093–1.433, P = 0.001), subsets of sCRC cases (G/A vs. G/G: OR = 1.204, 95% CI = 1.053–1.376, P = 0.007; G/A+A/A vs. G/G: OR = 1.188, 95% CI = 1.046–1.348, P = 0.008), subsets of Caucasian ethnicity (G/A vs. G/G: OR = 1.145, 95% CI = 1.004–1.306, P = 0.043; G/A+A/A vs. G/G: OR = 1.162, 95% CI = 1.026–1.316, P = 0.018), subsets of Duke’s stage C/D (A/A vs. G/G: OR = 1.275, 95% CI = 1.007–1.613, P = 0.043; G/A vs. G/G: OR = 1.365, 95% CI = 1.097–1.698, P = 0.005), subsets of the well/moderate degree of differentiation (G/A+A/A vs. G/G: OR = 1.337, 95% CI = 1.063–1.682, P = 0.013), male subjects (G/A vs. G/G: OR = 1.393, 95% CI = 1.073–1.809, P = 0.013; G/A+A/A vs. G/G: OR = 1.359, 95% CI = 1.080–1.710, P = 0.009), and subsets of the PCR-RFLP genotyping method (A/A vs. G/G: OR = 1.262, 95% CI = 1.126–1.415, P<0.001; G/A vs. G/G: OR = 1.190, 95% CI = 1.076–1.315, P = 0.001; G/A+A/A vs. G/G: OR = 1.216, 95% CI = 1.106–1.337, P<0.001). Specifically, the subgroup of Caucasian ethnicity was associated with 1.3- to 1.5-fold increased risk of sCRC without heterogeneity (A/A vs. G/G: OR = 1.511, 95% CI = 1.158–1.972, P = 0.002; G/A vs. G/G: OR = 1.307, 95% CI = 1.057–1.617, P = 0.014; G/A+A/A vs. G/G: OR = 1.369, 95% CI = 1.118–1.676, P = 0.002) ( Table 2 ).

Sensitivity Analyses

Sensitivity analyses was performed by omitting one study at a time. This procedure did not influence the pooled value, which supports the robustness of this current meta-analysis.

Publication Bias Analysis

The Begg’s funnel plot and the Egger’s test (A/A vs. G/G: P = 0.465; G/A vs. G/G: P = 0.731; G/A+A/A vs. G/G: P = 0.516; A/A vs. G/G+G/A: P = 0.399) showed no evidence of publication bias ( Figure 4 ).

Figure 4. Begg’s funnel plot [17] (GA vs. GG) for the identification of publication bias in all studies.

Figure 4

Open in a new tab

Assessment of Cumulative Evidence

We applied the Venice criteria [19] to evaluate the overall evidence of an association between the CCND1 G870A polymorphism and colorectal cancer susceptibility. The total sample size (6157 cases and 8198 controls) in our meta-analysis exceeded 1000. Therefore, we assigned the amount of evidence category an A grade. Next, we assessed the extent of replication. Our meta-analysis showed a significantly increased risk of colorectal cancer in the homozygote genetic model, the heterozygote genetic model and the dominant genetic model but not in the recessive model in any category. We observed minimal heterogeneity in the heterozygote genetic model and the dominant genetic model and moderate heterogeneity in the heterozygote genetic model. Therefore, we assigned a B grade for the extent of replication. Finally, there was no evidence of publication bias in our pooled data, and most of the included studies were well matched for race, ethnicity, gender and age. The summary ORs of each genetic model were greater than 1.15; therefore, bias could not have easily rendered the observed association. Nevertheless, most studies did not publish sufficient information about whether the G870A polymorphism was relevant to other polymorphisms or other candidate genes. Therefore, the Venice criterion of protection from bias was given a B grade. The overall grade of the Venice criteria for our data was “ABB”, which is consistent with moderate evidence demonstrating the linkage between the G870A polymorphism and colorectal cancer risk.

Discussion

Cell cycle regulation plays an important role in the evolution of cancer by influencing cell proliferation, differentiation and apoptosis [43]. It has been demonstrated in all eukaryotic organisms that the transition from the G1 phase to the S phase of the cell cycle is controlled by sequential activation of cyclin/cyclin-dependent kinase (Cdk) complexes [44]. The cyclin D1 locus (also called CCND1 or PRAD1, located on 11q13) consists of five exons and four introns and encodes cyclin D, a key regulatory protein promoting the transition through the restriction point in the G1 phase [45]. Over 250 single nucleotide polymorphisms (SNP) spanning CCND1 have been identified and cataloged in public SNP databases (dbSNP: www.ncbi.nlm.nih.gov/SNP/; HapMap: www.hapmap.org). Of the polymorphisms identified, the common adenine-to-guanine (A/G) substitution at nucleotide 870 in the conserved splice donor region of exon 4 has received the most investigation [6]. Normally, the G870 allele creates an optimal splice donor site and results in a well-described transcript for cyclin D1, termed cyclin D1a; however, the CCND1 G870A polymorphism at the boundary of exon 4 and intron 4 affects alternative splicing and results in an variant transcript for cyclin D1, termed cyclin D1b, which lacks exon 5 [6], [46], [47]. Therefore, cyclin D1b is homologous to cyclin D1a but lacks two regulatory motifs, the point estimation by sequential testing (PEST) domain and the threonine 286 phosphorylation site for glycogen synthase kinase 3ß, both of which are crucial in preventing the overexpression of cyclin D1 [6], [46], [47]. Excessive cyclin D1 activates CDK4/cyclin D1 complexes and initiates the phosphorylation of RB, which disrupts RB-mediated transcriptional repression of E2F and facilitates cell cycle progression [48], [49].

The current meta-analysis and systematic review summarizes the results from 22 case-control studies on the association of the CCND1 G870A polymorphism with CRC risk. A total of 6157 cases and 8198 controls were included. Based on the Venice criteria, the results indicated that the G/A or A/A genotype of CCND1 SNP rs603965 was significantly associated with an increased risk of CRC. Additionally, we found no significant risk of CRC associated with the CCND1 G870A polymorphism for the recessive model in any category, indirectly suggesting the linkage of the A-allele and increased CRC risk.

In the stratified analyses, the results showed that the association between the CCND1 G870A polymorphism and CRC risk remained significant in Caucasians and sCRC but not in Asians or HNPCC, which supports the hypothesis that genetic backgrounds and the environment in which patients live in might play important roles in the development of CRC [5]. Meanwhile, the finding that no association between the CCND1 genotype and CRC risk was observed in the comparison model of either the colon subgroup or the rectum subgroup was in contrast with the results from another meta-analysis investigating digestive tract cancers and the risk associated with the CCND1 G870A polymorphism [50]. We also found a significant association between G870A and CRC risk in a subset of hospital-based studies but not in the population-based studies. The lack of proper matching of controls among the studies might influence the consistency in our current results.

Meta-analysis is an important tool for revealing trends that might not be apparent in a single study. The pooling of independent but similar studies increases precision and therefore increases the confidence level of the findings. The current meta-analysis has some advantages. First, the number of total cases and controls was substantial, which significantly increased the statistical power of the analysis. Second, no publication biases were detected, which indicates that the entire pooled result may be unbiased.

Despite these advantages, some limitations in the current meta-analysis should be acknowledged. First, the controls were not uniformly defined. Although most of the patients in the control groups were selected from healthy populations, some might have had a benign disease. Therefore, there was a lack of proper matching, and the results are based on unadjusted estimates. The current meta-analysis is unable to solve problems with confounding factors that could be inherent in the included studies. Inadequate control of the confounders might bias the results either toward exaggeration or underestimation of risk estimates. Second, stratifying analyses were based on a relatively small number of studies from which detailed individual data were available; therefore, some of the subgroup analyses were difficult to perform. Third, although there is no indication of major publication bias in the formal evaluation used, potential publication bias is impossible to completely exclude because small studies with null results tend to not be published. Finally and mostly importantly, whether the CCND1 G870A polymorphism is independently predictive of cancer risk remains controversial [6], [51]. Thus, it should be noted that whether the A allele is a specific causal variant has yet to be determined. Some functional studies have demonstrated that the G allele can also produce transcript b (cyclin D1b), and the A allele can also produce transcript a (cyclin D1a)[22], [51], [52]; these results suggest that the A allele is not universally required for transcript b (cyclin D1b) production. Furthermore, one study demonstrated that the G870A and G1722C polymorphisms of cyclin D1 were in linkage disequilibrium in carcinomas of the head and neck [52]. Another study demonstrated that there was a synergistic effect between CCND1 G870A and caspase−8 6 n del/ins on CRC [40]. Therefore, it is possible that G870A is in linkage disequilibrium with another functional variant that modulates cancer risk. Additionally, there is no genome-wide association study (GWAS) identifying the susceptibility loci of CCND1 for colorectal cancer, although one group recently published a GWAS in which CCND1 was strongly suggestive in melanoma carcinogenesis [53]. Hence, large, prospective, population-based clinical trials and genome-wide association studies are required to validate the association of the CCND1 G870A polymorphism with CRC risk.

In conclusion, the current meta-analysis and systematic review demonstrated that the CCND1 G870A polymorphism is associated with CRC susceptibility, especially among patients of Caucasian ethnicity. The current results may prompt further investigation of diagnostic approaches and prevention strategies to combat CRC.

Acknowledgments

All procedures were performed in accordance with the Declaration of Helsinki. Informed consent was obtained from all patients, and the Institute Ethics Committee approved the study protocol.

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was financially sponsored by Shanghai Rising-Star Program (No.11QA1404800), grants from the National Natural Science Foundation of China (No.81001069) and the National 863 High Technology Foundation (No.2009AA02Z118). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. doi: 10.3322/caac.20073. [DOI] [PubMed] [Google Scholar]
  • 2.Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765–781. doi: 10.1016/j.ejca.2009.12.014. [DOI] [PubMed] [Google Scholar]
  • 3.Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–532. doi: 10.1056/NEJM198809013190901. [DOI] [PubMed] [Google Scholar]
  • 4.Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, et al. Colorectal cancer. Lancet. 2010;375:1030–1047. doi: 10.1016/S0140-6736(10)60353-4. [DOI] [PubMed] [Google Scholar]
  • 5.Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med. 2009;361:2449–2460. doi: 10.1056/NEJMra0804588. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 2006;25:1620–1628. doi: 10.1038/sj.onc.1209371. [DOI] [PubMed] [Google Scholar]
  • 7.Pabalan N, Bapat B, Sung L, Jarjanazi H, Francisco-Pabalan O, et al. Cyclin D1 Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human populations: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2008;17:2773–2781. doi: 10.1158/1055-9965.EPI-08-0169. [DOI] [PubMed] [Google Scholar]
  • 8.Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558. doi: 10.1002/sim.1186. [DOI] [PubMed] [Google Scholar]
  • 9.Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560. doi: 10.1136/bmj.327.7414.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–748. [PubMed] [Google Scholar]
  • 11.DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188. doi: 10.1016/0197-2456(86)90046-2. [DOI] [PubMed] [Google Scholar]
  • 12.Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 1988;7:889–894. doi: 10.1002/sim.4780070807. [DOI] [PubMed] [Google Scholar]
  • 13.Bax L, Ikeda N, Fukui N, Yaju Y, Tsuruta H, et al. More than numbers: the power of graphs in meta-analysis. Am J Epidemiol. 2009;169:249–255. doi: 10.1093/aje/kwn340. [DOI] [PubMed] [Google Scholar]
  • 14.L’Abbe KA, Detsky AS, O’Rourke K. Meta-analysis in clinical research. Ann Intern Med. 1987;107:224–233. doi: 10.7326/0003-4819-107-2-224. [DOI] [PubMed] [Google Scholar]
  • 15.Song F. Exploring heterogeneity in meta-analysis: is the L’Abbe plot useful? J Clin Epidemiol. 1999;52:725–730. doi: 10.1016/s0895-4356(99)00066-9. [DOI] [PubMed] [Google Scholar]
  • 16.Haber M. Exact significance levels of goodness-of-fit tests for the Hardy-Weinberg equilibrium. Hum Hered. 1981;31:161–166. doi: 10.1159/000153199. [DOI] [PubMed] [Google Scholar]
  • 17.Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–1101. [PubMed] [Google Scholar]
  • 18.Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634. doi: 10.1136/bmj.315.7109.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Ioannidis JP, Boffetta P, Little J, O’Brien TR, Uitterlinden AG, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol. 2008;37:120–132. doi: 10.1093/ije/dym159. [DOI] [PubMed] [Google Scholar]
  • 20.Kong S, Amos CI, Luthra R, Lynch PM, Levin B, et al. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res. 2000;60:249–252. [PubMed] [Google Scholar]
  • 21.McKay JA, Douglas JJ, Ross VG, Curran S, Murray GI, et al. Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal Initiative. Int J Cancer. 2000;88:77–81. doi: 10.1002/1097-0215(20001001)88:1<77::aid-ijc12>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  • 22.Bala S, Peltomaki P. CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res. 2001;61:6042–6045. [PubMed] [Google Scholar]
  • 23.Kong S, Wei Q, Amos CI, Lynch PM, Levin B, et al. Cyclin D1 polymorphism and increased risk of colorectal cancer at young age. J Natl Cancer Inst. 2001;93:1106–1108. doi: 10.1093/jnci/93.14.1106. [DOI] [PubMed] [Google Scholar]
  • 24.Porter TR, Richards FM, Houlston RS, Evans DG, Jankowski JA, et al. Contribution of cyclin d1 (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer. Oncogene. 2002;21:1928–1933. doi: 10.1038/sj.onc.1205245. [DOI] [PubMed] [Google Scholar]
  • 25.Grieu F, Malaney S, Ward R, Joseph D, Iacopetta B. Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res. 2003;23:4257–4259. [PubMed] [Google Scholar]
  • 26.Le Marchand L, Seifried A, Lum-Jones A, Donlon T, Wilkens LR. Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer. JAMA. 2003;290:2843–2848. doi: 10.1001/jama.290.21.2843. [DOI] [PubMed] [Google Scholar]
  • 27.Lewis RC, Bostick RM, Xie D, Deng Z, Wargovich MJ, et al. Polymorphism of the cyclin D1 gene, CCND1, and risk for incident sporadic colorectal adenomas. Cancer Res. 2003;63:8549–8553. [PubMed] [Google Scholar]
  • 28.Hong Y, Eu KW, Seow-Choen F, Fook-Chong S, Cheah PY. GG genotype of cyclin D1 G870A polymorphism is associated with increased risk and advanced colorectal cancer in patients in Singapore. Eur J Cancer. 2005;41:1037–1044. doi: 10.1016/j.ejca.2005.01.009. [DOI] [PubMed] [Google Scholar]
  • 29.Huang WS, Tang R, Lin PY, Changchien CR, Chen JS, et al. Impact of the cyclin D1 A870G polymorphism on susceptibility to sporadic colorectal cancer in Taiwan. Dis Colon Rectum. 2006;49:602–608. doi: 10.1007/s10350-005-0311-6. [DOI] [PubMed] [Google Scholar]
  • 30.Jiang J, Wang J, Suzuki S, Gajalakshmi V, Kuriki K, et al. Elevated risk of colorectal cancer associated with the AA genotype of the cyclin D1 A870G polymorphism in an Indian population. J Cancer Res Clin Oncol. 2006;132:193–199. doi: 10.1007/s00432-005-0039-7. [DOI] [PubMed] [Google Scholar]
  • 31.Kruger S, Engel C, Bier A, Mangold E, Pagenstecher C, et al. Absence of association between cyclin D1 (CCND1) G870A polymorphism and age of onset in hereditary nonpolyposis colorectal cancer. Cancer Lett. 2006;236:191–197. doi: 10.1016/j.canlet.2005.05.013. [DOI] [PubMed] [Google Scholar]
  • 32.Probst-Hensch NM, Sun CL, Van Den Berg D, Ceschi M, Koh WP, et al. The effect of the cyclin D1 (CCND1) A870G polymorphism on colorectal cancer risk is modified by glutathione-S-transferase polymorphisms and isothiocyanate intake in the Singapore Chinese Health Study. Carcinogenesis. 2006;27:2475–2482. doi: 10.1093/carcin/bgl116. [DOI] [PubMed] [Google Scholar]
  • 33.Schernhammer ES, Tranah GJ, Giovannucci E, Chan AT, Ma J, et al. Cyclin D1 A870G polymorphism and the risk of colorectal cancer and adenoma. Br J Cancer. 2006;94:928–934. doi: 10.1038/sj.bjc.6603007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Forones NM, de Lima JM, de Souza LG, da Silva ID. Cyclin D1 A870G polymorphism in Brazilian colorectal cancer patients. J Gastrointest Cancer. 2008;39:118–123. doi: 10.1007/s12029-009-9057-z. [DOI] [PubMed] [Google Scholar]
  • 35.Grunhage F, Jungck M, Lamberti C, Berg C, Becker U, et al. Association of familial colorectal cancer with variants in the E-cadherin (CDH1) and cyclin D1 (CCND1) genes. Int J Colorectal Dis. 2008;23:147–154. doi: 10.1007/s00384-007-0388-6. [DOI] [PubMed] [Google Scholar]
  • 36.Talseth BA, Ashton KA, Meldrum C, Suchy J, Kurzawski G, et al. Aurora-A and Cyclin D1 polymorphisms and the age of onset of colorectal cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer. 2008;122:1273–1277. doi: 10.1002/ijc.23177. [DOI] [PubMed] [Google Scholar]
  • 37.Tan XL, Nieters A, Kropp S, Hoffmeister M, Brenner H, et al. The association of cyclin D1 G870A and E-cadherin C-160A polymorphisms with the risk of colorectal cancer in a case control study and meta-analysis. Int J Cancer. 2008;122:2573–2580. doi: 10.1002/ijc.23363. [DOI] [PubMed] [Google Scholar]
  • 38.Jelonek K, Gdowicz-Klosok A, Pietrowska M, Borkowska M, Korfanty J, et al. Association between single-nucleotide polymorphisms of selected genes involved in the response to DNA damage and risk of colon, head and neck, and breast cancers in a Polish population. J Appl Genet. 2010;51:343–352. doi: 10.1007/BF03208865. [DOI] [PubMed] [Google Scholar]
  • 39.Kanaan Z, Eichenberger MR, Young M, Colliver D, Crawford N, et al. An alternative cyclin-D1 splice site is not linked to inflammatory bowel disease-associated neoplasia. Int J Biol Markers. 2010;25:27–31. doi: 10.1177/172460081002500104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Liu B, Zhang Y, Jin M, Ni Q, Liang X, et al. Association of selected polymorphisms of CCND1, p21, and caspase8 with colorectal cancer risk. Mol Carcinog. 2010;49:75–84. doi: 10.1002/mc.20579. [DOI] [PubMed] [Google Scholar]
  • 41.Yaylim-Eraltan I, Arikan S, Yildiz Y, Cacina C, Ergen HA, et al. The influence of cyclin D1 A870G polymorphism on colorectal cancer risk and prognosis in a Turkish population. Anticancer Res. 2010;30:2875–2880. [PubMed] [Google Scholar]
  • 42.Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–2012. doi: 10.1001/jama.283.15.2008. [DOI] [PubMed] [Google Scholar]
  • 43.Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411:342–348. doi: 10.1038/35077213. [DOI] [PubMed] [Google Scholar]
  • 44.Ekholm SV, Reed SI. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol. 2000;12:676–684. doi: 10.1016/s0955-0674(00)00151-4. [DOI] [PubMed] [Google Scholar]
  • 45.Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, et al. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995;11:1005–1011. [PubMed] [Google Scholar]
  • 46.Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res. 2003;63:7056–7061. [PubMed] [Google Scholar]
  • 47.Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, et al. Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem. 2003;278:30339–30347. doi: 10.1074/jbc.M303969200. [DOI] [PubMed] [Google Scholar]
  • 48.Gerard C, Goldbeter A. Temporal self-organization of the cyclin/Cdk network driving the mammalian cell cycle. Proc Natl Acad Sci U S A. 2009;106:21643–21648. doi: 10.1073/pnas.0903827106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Berthet C, Klarmann KD, Hilton MB, Suh HC, Keller JR, et al. Combined loss of Cdk2 and Cdk4 results in embryonic lethality and Rb hypophosphorylation. Dev Cell. 2006;10:563–573. doi: 10.1016/j.devcel.2006.03.004. [DOI] [PubMed] [Google Scholar]
  • 50.Chen B, Cao L, Yang P, Zhou Y, Wu XT. Cancer Epidemiol; 2011. Cyclin D1 (CCND1) G870A gene polymorphism is an ethnicity-dependent risk factor for digestive tract cancers: A meta-analysis comprising 20,271 subjects. [DOI] [PubMed] [Google Scholar]
  • 51.Comstock CE, Augello MA, Benito RP, Karch J, Tran TH, et al. Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin Cancer Res. 2009;15:5338–5349. doi: 10.1158/1078-0432.CCR-08-2865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Holley SL, Parkes G, Matthias C, Bockmuhl U, Jahnke V, et al. Cyclin D1 polymorphism and expression in patients with squamous cell carcinoma of the head and neck. Am J Pathol. 2001;159:1917–1924. doi: 10.1016/S0002-9440(10)63038-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Barrett JH, Iles MM, Harland M, Taylor JC, Aitken JF, et al. Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet. 2011;43:1108–1113. doi: 10.1038/ng.959. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES